Ember receives options for brown fat IP

Ember Therapeutics Inc. (Boston, Mass.) received exclusive options to IP for three targets related to its brown fat small molecule drug discovery program. Brigham and Women's Hospital gave the company an option for IP surrounding aldehyde dehydrogenase 1 family member A1 (ALDH1A1) and thioesterase superfamily member 1 (THEM1). Dana Farber Cancer Institute granted Ember an option to IP surrounding transient receptor potential vanilloid 4 ( TRPV4; VRL2). Ember declined to provide financial terms.

Ember said ALDH1A1 induces brown fat-like attributes in white fat tissue. THEM1 is involved in regulation of energy homeostasis. Ember also said inhibition of TRPV4 leads to activation of brown fat and protection from diet-induced obesity, inflammation and insulin resistance. ...